Psoriasis Plus Accelerated Biological Aging Triples Cardiovascular Death Risk
A large NHANES cohort study finds that psoriasis patients with accelerated phenotypic aging face dramatically higher all-cause and CVD mortality.
Summary
Researchers analyzed 11,443 US adults from NHANES (2003–2010) to explore how psoriasis and phenotypic age acceleration (PhenoAge-accel) jointly affect mortality. PhenoAge-accel — calculated from inflammatory and immune biomarkers versus chronological age — was significantly associated with higher psoriasis odds. Over a median follow-up of nearly 11 years, individuals with both psoriasis and accelerated biological aging had a 2.70-fold higher all-cause mortality risk and similar elevation in cardiovascular death risk compared to healthy controls. The findings suggest these two conditions interact synergistically, compounding mortality risk beyond what either condition produces alone, highlighting the importance of biological age assessment in psoriasis management.
Detailed Summary
Psoriasis is far more than a skin condition — it is a chronic, systemic inflammatory disease linked to cardiovascular disease, metabolic syndrome, and premature death. Understanding which co-existing biological factors amplify mortality risk is critical to improving patient outcomes. This study tackled a largely unexplored question: do psoriasis and accelerated biological aging act together to significantly worsen survival?
Using data from 11,443 adults enrolled in the National Health and Nutrition Examination Survey (NHANES) during 2003–2006 and 2009–2010, researchers conducted both cross-sectional and longitudinal analyses. Phenotypic age acceleration (PhenoAge-accel) was derived by subtracting an individual's chronological age from their calculated 'phenotypic age,' which integrates nine biomarkers including white blood cell count, C-reactive protein, albumin, creatinine, glucose, red blood cell distribution width, mean corpuscular volume, alkaline phosphatase, and lymphocyte percentage. A PhenoAge-accel ≥ 0 defined accelerated aging (PhenoAge-accel+). Mortality was tracked through linkage to the National Death Index through December 31, 2019.
At baseline, 312 participants (2.73%) had psoriasis. After full covariate adjustment, those with PhenoAge-accel+ had 83% higher odds of having psoriasis (OR 1.83, 95% CI 1.36–2.45) compared to those with PhenoAge-accel−. Restricted cubic spline analysis confirmed a roughly linear positive relationship between PhenoAge-accel and psoriasis risk. Participants were then stratified into four groups: psoriasis−/PhenoAge-accel− (reference), psoriasis+/PhenoAge-accel−, psoriasis−/PhenoAge-accel+, and psoriasis+/PhenoAge-accel+.
Over a median follow-up of 10.91 years, 1,059 all-cause deaths and 306 CVD deaths occurred. In fully adjusted Cox proportional hazards models, the psoriasis−/PhenoAge-accel+ group showed an 80% increase in all-cause mortality risk (HR 1.80, 95% CI 1.54–2.10), while psoriasis alone (psoriasis+/PhenoAge-accel−) showed no significant elevation (HR 0.96, 95% CI 0.56–1.65). Strikingly, the combination of psoriasis and accelerated aging (psoriasis+/PhenoAge-accel+) yielded an HR of 2.70 (95% CI 1.66–4.39) for all-cause mortality — suggesting a synergistic interaction. CVD mortality followed a similar pattern. Sensitivity analyses excluding the first two years of follow-up and participants with missing covariates confirmed the robustness of these results.
These findings imply that biological aging acceleration — quantifiable from routine blood biomarkers — is not only associated with psoriasis risk but substantially amplifies the mortality burden in psoriasis patients. The lack of significant mortality elevation in psoriasis patients without accelerated aging suggests PhenoAge-accel may be a key mediating or moderating factor. Clinically, this underscores the potential value of routine biological age assessment in psoriasis patients to stratify long-term cardiovascular and mortality risk. Key caveats include the self-reported psoriasis diagnosis, cross-sectional psoriasis ascertainment, and possible residual confounding.
Key Findings
- Accelerated phenotypic aging (PhenoAge-accel+) was associated with 83% higher odds of psoriasis after full covariate adjustment.
- Psoriasis alone (without accelerated aging) did not significantly increase all-cause or CVD mortality risk.
- Coexisting psoriasis and PhenoAge-accel+ increased all-cause mortality risk by 2.70-fold vs. healthy controls.
- Accelerated biological aging alone raised all-cause mortality risk by 1.80-fold, with a similar trend for CVD mortality.
- PhenoAge-accel is calculable from nine routine blood biomarkers, making it a clinically accessible aging metric.
Methodology
This prospective cohort study used NHANES data (2003–2006, 2009–2010) with 11,443 adults, employing weighted multivariable logistic regression for cross-sectional psoriasis-aging associations and Cox proportional hazards models for mortality outcomes. Mortality was ascertained via National Death Index linkage through December 31, 2019, with a median follow-up of 10.91 years.
Study Limitations
Psoriasis was self-reported (physician diagnosis recall), which may introduce misclassification bias, and psoriasis severity was not captured. The study cannot establish causality due to its observational design, and residual confounding from unmeasured variables such as psoriasis treatment type or disease duration cannot be excluded.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: